Synthesis of 1-Hydroxy(and 1-Alkoxy, 1-Acyloxy)-1H-Indoles and Evaluations of their Suppressive Activities against Tumor Growth through Inhibiting Lactate Dehydrogenase A
Se-Yun Cheon, Ye Eun Kim, Eun-Sun Yang, Yoo Jin Lim, Chang-Hwan Bae, Jung-Sook Jin, Wonyoung Park, Bo-Sung Kim, Chorong Kim, Hyunsung Cho, Seungtae Kim, Sang Hyup Lee, Ki-Tae Ha
{"title":"Synthesis of 1-Hydroxy(and 1-Alkoxy, 1-Acyloxy)-1H-Indoles and Evaluations of their Suppressive Activities against Tumor Growth through Inhibiting Lactate Dehydrogenase A","authors":"Se-Yun Cheon, Ye Eun Kim, Eun-Sun Yang, Yoo Jin Lim, Chang-Hwan Bae, Jung-Sook Jin, Wonyoung Park, Bo-Sung Kim, Chorong Kim, Hyunsung Cho, Seungtae Kim, Sang Hyup Lee, Ki-Tae Ha","doi":"10.1016/j.ejmech.2024.117104","DOIUrl":null,"url":null,"abstract":"Inhibition of lactate dehydrogenase (LDH) has emerged as a promising cancer therapy strategy due to its essential role in the metabolic transformation of cancer cells. In this study, 53 derivatives of 1-hydroxy(and 1-alkoxy, 1-acyloxy)indoles were designed, synthesized, and biologically evaluated. Several multi-substituted 1-hydroxy(and 1-alkoxy, 1-acyloxy)indole compounds exhibited inhibitory activity against the LDH-A isoform (LDHA). We confirmed that the C(3)-substituent provided additional significant hydrogen bonding and hydrophobic interactions, which enhanced the LDHA inhibitory activity with high selectivity. Our results revealed that methyl 4-bromo-3-[(<em>n</em>-hexyloxy)methyl]-1-hydroxy-1<em>H</em>-indole-2-carboxylate (<strong>1g</strong>), selectively inhibited LDHA (IC<sub>50</sub> = 25 ± 1.12 nM) without affecting the LDH-B isoform (LDHB). The compound exhibited potent cytotoxic activity in several cancer cell lines, including DLD-1 colorectal cancer cells (GI<sub>50</sub> = 27 ± 1.2 μM). Compound <strong>1g</strong> significantly inhibited cancer cell growth by activating apoptotic pathways in a xenograft cancer model, without causing weight loss or liver and kidney damage. Therefore, compound <strong>1g</strong> may serve as a highly specific and promising candidate for the development of LDHA inhibitors for cancer therapy.","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"77 1","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ejmech.2024.117104","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
Inhibition of lactate dehydrogenase (LDH) has emerged as a promising cancer therapy strategy due to its essential role in the metabolic transformation of cancer cells. In this study, 53 derivatives of 1-hydroxy(and 1-alkoxy, 1-acyloxy)indoles were designed, synthesized, and biologically evaluated. Several multi-substituted 1-hydroxy(and 1-alkoxy, 1-acyloxy)indole compounds exhibited inhibitory activity against the LDH-A isoform (LDHA). We confirmed that the C(3)-substituent provided additional significant hydrogen bonding and hydrophobic interactions, which enhanced the LDHA inhibitory activity with high selectivity. Our results revealed that methyl 4-bromo-3-[(n-hexyloxy)methyl]-1-hydroxy-1H-indole-2-carboxylate (1g), selectively inhibited LDHA (IC50 = 25 ± 1.12 nM) without affecting the LDH-B isoform (LDHB). The compound exhibited potent cytotoxic activity in several cancer cell lines, including DLD-1 colorectal cancer cells (GI50 = 27 ± 1.2 μM). Compound 1g significantly inhibited cancer cell growth by activating apoptotic pathways in a xenograft cancer model, without causing weight loss or liver and kidney damage. Therefore, compound 1g may serve as a highly specific and promising candidate for the development of LDHA inhibitors for cancer therapy.
期刊介绍:
The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers.
A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.